What is ARA-290, and what is it studied for?
ARA-290, known in pharmacology as cibinetide, is an eleven-residue peptide derived from the helix B surface of erythropoietin, formula C51H84N16O21, mass 1257.3, CAS 1208243-50-8, with an N-terminal pyroglutamate. It binds the innate repair receptor, a complex of the erythropoietin receptor and the beta common receptor, without the haematopoietic activity of the parent hormone, and is studied in cell and rodent models of tissue protection. The current certificate's size label reads 16 mg against a 10 mg product; this guide states that. The material is for in-vitro research only.
What is the structure of ARA-290?
Eleven residues with a pyroglutamate N-terminus that blocks Edman sequencing, three acidic residues and a net negative charge at neutral pH. The sequence reproduces the spatial arrangement of helix B's aqueous face as a linear peptide. Mass 1257.3 is confirmed by LC-MS/MS on the current certificate.
| Identifier | Value |
|---|---|
| Molecular formula | C51H84N16O21 |
| Molecular weight | 1257.3 g/mol |
| Residues | 11 |
| CAS number | 1208243-50-8 |
| PubChem CID | 91810664 |
| Current lot | ARA2901-0803 |
How is ARA-290 thought to work?
Agonist at the heteromeric innate repair receptor, activating tissue-protective signalling through JAK2 and downstream pathways without engaging the homodimeric erythropoietin receptor that drives red-cell production; Brines and colleagues described the design and the receptor selectivity in 2008.
Which research areas use ARA-290?
| Area | Typical models and endpoints |
|---|---|
| Innate repair receptor pharmacology | Signalling assays in cells expressing the EPO receptor and beta common receptor. |
| Tissue-protection models | Rodent models of ischaemic and inflammatory injury. |
| Erythropoietin fragment design | Helix-B-derived peptides as a case study in separating receptor activities. |
| Pyroglutamate peptide chemistry | Identity and sequencing considerations for a blocked N-terminus. |
What does the published literature show?
Brines et al. (PNAS, 2008) described the helix-B peptides and their non-erythropoietic tissue-protective activity in cells and animals. Cibinetide has been studied in regulated early-phase trials, which describe a pharmaceutical candidate and are context only. There is no approved product; research use is in-vitro and preclinical.
How is ARA-290 handled in the laboratory?
Dissolves in water; a slightly basic buffer helps because of the acidic residues. No methionine or cysteine. Store lyophilized at minus 20 °C; aliquot and freeze; low-binding tubes at low concentration. The concentration table covers volumes and syringe units; the storage guide covers stability by compound class.
What does the current certificate show?
Lot ARA2901-0803 tested at 99.72% purity by RP-HPLC (214 nm), identity confirmed by LC-MS/MS, endotoxin <0.05 EU/mL. The certificate is in the COA library and the lot number on the vial matches it. Sold as 10 mg per vial at $82, for laboratory research only.
Certificate history for ARA-290
Every certificate the library holds for this compound, newest first. A replaced lot stays listed so the history can be read; the certificate dataset reads all 114 together.
| Lot | Issued | Size | Identity | Purity | Content | Status |
|---|---|---|---|---|---|---|
| ARA2901-0803 | Aug 17, 2026 | 16 mg | LC-MS/MS | 99.72% | 10.86 mg | Current |
| ARA290-0616 | Jun 25, 2026 | 16 mg | MALDI-MS | 99.9% | 16.39 mg | Replaced |
Frequently asked questions
Why does the certificate say 16 mg?
Because the laboratory's size label for lot ARA2901-0803 reads 16 mg while the product is sold as 10 mg, and the measured content of 10.86 mg agrees with the product. The certificate post flags it; a corrected certificate has been requested.
What does the current certificate show?
Lot ARA2901-0803: identity by LC-MS/MS at 1257.1, purity 99.72% by RP-HPLC at 214 nm, content 10.86 mg, endotoxin below 0.05 EU/mL. Issued 17 August 2026.
Does ARA-290 raise red-cell production?
Not in the models that defined it; the point of the helix-B design is to engage the innate repair receptor without the homodimeric erythropoietin receptor.
References
- Brines M, Patel NS, Villa P, et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA. 2008;105(31):10925-10930.
- PubChem CID 91810664, Cibinetide. National Library of Medicine. Read 2 October 2026.
Clinical results cited above describe regulated trials of pharmaceutical products and are given as context for research interest only. Nothing on this page describes or recommends use of the material sold here in humans or animals.
ARA-290 10 mg
$82 per vial
Lot ARA2901-0803 · 99.72% RP-HPLC (214 nm) · certificate published
View productRelated
- BPC-157 research guide · BPC-157 5 mg
- TB-500 research guide · TB-500 5 mg
- ARA-290 (cibinetide): an eleven-residue peptide taken from the surface of erythropoietin, the certificate for lot ARA2901-0803, and what the mass confirms
- What 114 certificates of analysis show: purity, content, methods and turnaround across every Pepstral lot, as a dataset
- Vilon (Lys-Glu): a two-residue peptide, the certificate for lot VILON20-0528, and why a dipeptide is sold in 20 mg vials
- DSIP: the nine-residue sequence, the 1977 rabbit experiments, the receptor nobody has found, and what a 5 mg certificate shows
- Glossary of certificate terms
